Cargando…
Trimetazidine Inhibits Renal Tubular Epithelial Cells to Mesenchymal Transition in Diabetic Rats via Upregulation of Sirt1
Trimetazidine (TMZ), as a metabolic regulator, is effective in treatment of coronary atherosclerotic heart disease with rare side effects in the clinic for long years. Interestingly, studies have shown that TMZ protects against several acute kidney injuries (AKI). However, the effect of TMZ on chron...
Autores principales: | Yang, Yong, Wang, Yong, He, Zuowen, Liu, Yunchang, Chen, Chen, Wang, Yan, Wang, Dao Wen, Wang, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403491/ https://www.ncbi.nlm.nih.gov/pubmed/32848753 http://dx.doi.org/10.3389/fphar.2020.01136 |
Ejemplares similares
-
Trimetazidine in Heart Failure
por: Shu, Hongyang, et al.
Publicado: (2021) -
Inhibition of Renal Tubular Epithelial Mesenchymal Transition and Endoplasmic Reticulum Stress-Induced Apoptosis with Shenkang Injection Attenuates Diabetic Tubulopathy
por: Wang, Wen-Wen, et al.
Publicado: (2021) -
Gremlin Regulates Tubular Epithelial to Mesenchymal Transition via VEGFR2: Potential Role in Renal Fibrosis
por: Marquez-Exposito, Laura, et al.
Publicado: (2018) -
20(S)-Protopanaxadiol Inhibits Angiotensin II-Induced Epithelial- Mesenchymal Transition by Downregulating SIRT1
por: Wang, Yuchen, et al.
Publicado: (2019) -
Trimetazidine Attenuates Heart Failure by Improving Myocardial Metabolism via AMPK
por: Shu, Hongyang, et al.
Publicado: (2021)